文献速递膀胱癌与上尿路尿路上皮癌

卡博替尼联合帕博利珠单抗一线治疗顺铂不耐受晚期尿路上皮癌:PemCab试验

Cabozantinib plus Pembrolizumab as First-line Therapy for Cisplatin-ineligible Advanced Urothelial Carcinoma: The PemCab Trial.
PubMed 文献 · Eur Urol Oncol · 2025-04-29

这项开放标签、单臂、多中心2期研究评估帕博利珠单抗联合卡博替尼一线治疗顺铂不耐受的晚期尿路上皮癌。35例可评估患者中客观缓解率为46%(95%CI 31-62%),中位无进展生存期8个月,中位总生存期17个月,毒性可控。

要点

  • 联合方案在顺铂不耐受晚期尿路上皮癌中客观缓解率达46%。
  • 中位无进展生存期8个月,中位总生存期17个月。
  • 常见不良事件为腹泻、疲劳、瘙痒等,总体毒性可控。

核心结论

  • 帕博利珠单抗联合卡博替尼一线治疗顺铂不耐受晚期尿路上皮癌显示可控毒性和有前景的疗效。

研究设计与样本

  • 开放标签、单臂、多中心2期研究,35例可评估患者接受帕博利珠单抗200 mg每3周联合卡博替尼40 mg每日一次。

主要发现

  • 35例可评估患者中16例出现缓解,客观缓解率46%(95%CI 31-62%)。
  • 中位无进展生存期8个月(95%CI 5-13),中位总生存期17个月(95%CI 13-未达到)。
  • 任何级别最常见治疗中出现的不良事件为腹泻(58%)、疲劳(56%)、瘙痒(39%)、恶心(36%)、掌跖红斑感觉异常(36%)和食欲下降(33%)。

关键数值与推荐

  • 关键纳入标准为局部晚期或转移性尿路上皮癌、ECOG体能状态0-2、不适合或拒绝顺铂、既往未接受PD-1/L1抑制剂。
  • 主要终点为客观缓解率,次要终点包括无进展生存期和总生存期。

临床怎么用

  • 对于顺铂不耐受的晚期尿路上皮癌患者,帕博利珠单抗联合卡博替尼可作为一线治疗选择之一。

局限性

  • 单臂2期研究,样本量较小(35例可评估),缺乏随机对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Pembrolizumab monotherapy is approved for patients with platinum-ineligible metastatic urothelial carcinoma (mUC). Cabozantinib is a multireceptor tyrosine kinase inhibitor with activity against MET and VEGFR2 and is approved as monotherapy or in combination with a PD-1 inhibitor for other malignancies. The objective was to determine the safety and efficacy of pembrolizumab + cabozantinib as first-line treatment for patients with mUC. METHODS: In this open-label, single-arm, multicenter, phase 2 study, patients received pembrolizumab 200 mg every 3 wk + cabozantinib 40 mg daily. Key inclusion criteria were locally advanced UC or mUC, Eastern Cooperative Oncology Group performance status 0-2, ineligible for or refused cisplatin, and no prior PD-1/L1 inhibitor. The primary endpoint was the objective response rate (ORR). Secondary endpoints included progression-free survival (PFS) and overall survival (OS). According to the statistical plan, in a cohort of 35 evaluable participants, the lower bound of the 95% confidence interval (CI) would extend no more than 26% from the ORR observed, and in a scenario with ≥17 objective responses, the CI would exclude 32%. KEY FINDINGS AND LIMITATIONS: Responses were observed in 16 of 35 evaluable patients, with an ORR of 46% (95% CI 31-62%). Median PFS and OS were 8 mo (95% CI 5-13) and 17 mo (95% CI 13-not reached), respectively. The most common treatment-emergent adverse events (any grade) were diarrhea (58%), fatigue (56%), pruritus (39%), nausea (36%), palmar-plantar erythrodysesthesia (36%), and a decrease in appetite (33%). CONCLUSIONS AND CLINICAL IMPLICATIONS: This phase 2 trial of pembrolizumab + cabozantinib demonstrated a manageable toxicity profile and promising efficacy as a first-line therapy combination for cisplatin-ineligible patients with mUC.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Jain RK, Swami U, Bilen MA, et al. Cabozantinib plus Pembrolizumab as First-line Therapy for Cisplatin-ineligible Advanced Urothelial Carcinoma: The PemCab Trial. Eur Urol Oncol. 2025. PMID: 40307092. doi:10.1016/j.euo.2025.04.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。